Cartesian Therapeutics, Inc. (RNAC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.27+1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNAC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance and complete the Phase 3 AURORA trial in myasthenia gravis with topline data expected in Q1 2027 and BLA filing planned for mid-2027.
Stated as a priority in 2 of last 2 quarters. The Phase 3 AURORA trial in myasthenia gravis is ongoing with topline data expected in Q1 2027 and a biologics license application filing planned for mid-2027. Management has consistently emphasized this trial as the top priority and the trajectory is delivering as enrollment and trial progress continue.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027”
“Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis”
Progress the Phase 2 TRITON trial of Descartes-08 in myositis with clinical data from a subset of patients expected in the first half of 2027.
Stated as a priority in 2 of last 2 quarters. The Phase 2 TRITON trial in myositis is progressing with enrollment ongoing and clinical data from a subset of patients expected in the first half of 2027. Management's statements and trial initiation confirm active advancement, indicating delivery on this priority.
“Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27”
“Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated”
Continue enrollment and progress in the Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis with data expected in the first half of 2027.
Stated as a priority in 2 of last 2 quarters. The Phase 1/2 HELIOS pediatric trial is ongoing with enrollment progressing and clinical data expected in the first half of 2027. Management's repeated emphasis and trial activity indicate delivery on this priority.
“Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27”
“Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis”
Secure financing and manage cash resources to support planned operations, including clinical trials, into mid-2027 and extended to 2028.
Stated as a priority in 3 of last 3 quarters. Cash resources increased from approximately $120.4 million at 2026-Q1 to $149.3 million at 2026-Q2, supported by $150 million non-dilutive financing from K2 HealthVentures. Management has extended the cash runway into 2028, delivering on the commitment to maintain financial resources for operations and clinical programs.
“Approximately $149.3 million cash as of June 30, 2026, expected to support planned operations into 2028”
“Approximately $120.4 million cash as of March 31, 2026, expected to support planned operations into mid-2027”
“Cash, cash equivalents and restricted cash as of December 31, 2025 was $126.9 million and expected to support operations into mid-2027”
Advance development of in vivo CAR-T therapies using WestGene's targeted lipid nanoparticle platform with clinical trial initiation in 2H 2026 and data expected in 1H 2027.
Newly stated in 2026-Q2. Cartesian announced a strategic licensing agreement with WestGene to develop in vivo CAR-T therapies, with a Phase 1 trial expected to start in the second half of 2026 and clinical data anticipated in the first half of 2027. This is a new strategic priority with initial progress consistent with management's stated plans.
“Strategic partnership with WestGene to develop in vivo CAR-T therapies; Phase 1 trial expected to initiate in 2H 2026 with clinical data expected in 1H 2027”
Over the trailing year it converted 0.29x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.